Skip to Main Content

A majority of U.S. physicians disagree with the decision by the Food and Drug Administration to approve the Alzheimer’s drug from Biogen (BIIB) and believe the medicine should not be routinely used for patients, according to a new survey from STAT and Medscape.

In addition, nearly two-thirds of the 200 primary care physicians and neurologists polled said they find the trial data unclear when it comes to the benefits and risks of the drug, which is called Aduhelm. Consequently, only a small minority of these doctors think the medicine should be given to patients with early-onset Alzheimer’s, the patient population that was studied by the drug maker.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment